W

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Business Management
Share
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Source：MarketWatch

Disclaimer：Please read market information rationally and stay aware of investment risks. All content on this site is for informational purposes only and does not constitute investment advice.

Related Reading

US Republicans send ‘final’ CLARITY Act offer to Democrats

The 635page revised proposal includes Trumpbacked ethics provisions and comes just two days before a key procedural vote. Source：Cointelegraph

Revolut attackers threaten daily customer data leaks

Attackers reportedly published identity documents and selfies belonging to Revolut customers and threatened to release more data each day until the fintech…

Crypto’s biggest week ever? Swarm fears prompt AI slowdown: Hodler’s Digest

Crypto’s moment of CLARITY finally arrives with a key Senate vote on Tuesday. AI swarm fears prompt development slowdown, with some predicting big falls in AI…

Fed rate hikes won’t bring down gas prices. Why the bond market is pushing for them anyway.

The 10year Treasury yield is sitting on the doorstep of 5%, and that’s a warning sign for stocks. Source：MarketWatch

Source：https://www.marketwatch.com/story/how-ozempic-maker-novo-nordisk-blew-its-lead-in-glp-1-weight-loss-drugs-can-europe-compete-in-the-high-stakes-global-economy-0a2bcfd0